cbdMD (YCBD) Net Income towards Common Stockholders Growth (3y) (2019 - 2026)
cbdMD (YCBD) Net Income towards Common Stockholders Growth (3y) (2019 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.51 Bn | 43.55 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.52 Bn | 39.86 Bn | 2.15 Bn | 14.04% |
| 3 | Zoetis | 32.43 Bn | 30.75 Bn | 1.05 Bn | -0.23% |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn | 2.87% |
| 5 | United Therapeutics | 21.87 Bn | 19.21 Bn | 683.80 Mn | 8.71% |
| 6 | Viatris | 18.98 Bn | 18.09 Bn | 1.46 Bn | -34.81% |
| 7 | Neurocrine Biosciences | 15.43 Bn | 15.04 Bn | 935.80 Mn | 14.78% |
| 8 | Elanco Animal Health | 12.02 Bn | 11.49 Bn | 798.00 Mn | 36.74% |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - | - |
| 10 | cbdMD | 5.41 Mn | 3.29 Mn | 3.04 Mn | 24.38% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 24.38% |
| Dec 31, 2025 | 59.69% |
| Sep 30, 2025 | 64.83% |
| Jun 30, 2025 | 66.48% |
| Mar 31, 2025 | 36.03% |
| Dec 31, 2024 | 63.44% |
| Sep 30, 2024 | 35.77% |
| Jun 30, 2024 | -36.68% |
| Mar 31, 2024 | 32.55% |
| Dec 31, 2023 | 40.53% |
| Sep 30, 2023 | -38.45% |
| Jun 30, 2023 | 32.61% |
| Mar 31, 2023 | -29.23% |
| Dec 31, 2022 | -33.61% |
| Sep 30, 2022 | -50.36% |
| Jun 30, 2022 | -5.62% |
| Mar 31, 2022 | 43.75% |
| Dec 31, 2021 | -112.20% |
| Sep 30, 2021 | -69.86% |
| Jun 30, 2021 | 67.99% |